Co-dosing with long acting PYY(3–36) and the GLP-1 receptor agonists has potential as an efficient obesity treatment as food intake and body weight is synergistically or at least additively reduced in animal models [[1], [2], [3], [4], [5], [35], [36]]. Here, PYY is linked to obesity due to melanocortin 4 receptor deficiency.